**Question:** Warthins tumor is

A. Lymphosarcoma
B. Squamous cell carcinoma
C. Papillary thyroid carcinoma
D. Non-Hodgkin lymphoma

**Correct Answer:** D. Non-Hodgkin lymphoma

**Core Concept:**

Warthin's tumor is a benign salivary gland tumor characterized by the proliferation of lymphoid tissue and mucous cells. It represents a mixed tumor consisting of benign lymphoid follicles and epithelial cells. This type of tumor typically affects the parotid gland and is named after the British pathologist Thomas Warthin, who first described it in 1919.

**Why the Correct Answer is Right:**

Warthin's tumor is classified as a non-Hodgkin lymphoma (NHL), specifically a lymphoepithelial lesion. NHL is a group of cancers that affect the lymphocytes (white blood cells) in the body. This classification is based on the presence of lymphoid tissue and the composition of the tumor, which includes both lymphoid follicles and epithelial cells.

**Why Each Wrong Option is Incorrect:**

A. Lymphosarcoma (also known as lymphoma) is another term for NHL, but it does not specifically describe a tumor with both lymphoid tissue and epithelial cells, making it an incorrect choice.

B. Squamous cell carcinoma is a cancer affecting squamous cells, which are a type of epithelial cell, not lymphoid tissue. This choice is incorrect due to the absence of lymphoid tissue in the tumor.

C. Papillary thyroid carcinoma is a type of cancer that affects the thyroid gland, not salivary glands. This choice is incorrect as it is unrelated to the salivary gland tumors.

**Clinical Pearl:**

Understanding the pathological features of Warthin's tumor is crucial for accurate diagnosis, particularly in cases where a patient presents with a salivary gland mass. This knowledge helps differentiate between various types of salivary gland tumors, such as Warthin's tumor, mucoepidermoid carcinoma (a salivary gland cancer with mixed epithelial and mesenchymal components), and pleomorphic adenoma (a benign mixed tumor involving both epithelial and myoepithelial cells). By recognizing these entities, clinicians can tailor treatment strategies and prognosis for patients.